Ecovyst Inc. (ECVT): what the price requires

At today's price, Ecovyst Inc. (ECVT) is priced for +12.7% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-19 · Source: https://boothcheck.com/report/ECVT

Headline

FieldValue
TickerECVT
CompanyEcovyst Inc.
Current price$11.88/sh

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin needed9.0%
Operating margin today9.9%
Margin compression implied-0.9pp
Implied growth12.7%
Multiple paid16x operating income

The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.

Solve inputs: computed at a 9.8% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~6.2pp.

How unusual the bet is: within-range

ReferenceValue
vs own history-0.03σ
cohort percentile (of 74 peers)38
sustained it ~5 years at this level55%
implied end-window share0%

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset2.56x3expensive
Earnings2.39x3expensive
Relative1.08x3expensive
Growth0.51x4justifies

Families that justify the price: Relative, Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.1%); the inversion above states its own rate.

Per-Model Detail (n=13)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$60.080.20xyesFCF base $0.1B, growth 23% (input: historical growth), terminal g 4.0%, WACC 7.1%, 7yr projection
DCF Exit MultipleGrowth$22.060.54xyesExit EV/EBITDA: 11.1x / 13.1x / 15.1x (bear / base = today's held flat / bull), 7yr
Relative ValuationRelative$10.991.08xyesP/S fallback (negative EPS): Sector P/S 1.5x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$5.152.31xyesBook value floor: BV/sh $5.15, ROE negative
Two-Stage Excess ReturnAsset$4.632.56xyesBook value with convergence: BV/sh $5.15, ROE converges to ke
Discounted Future Market CapGrowth$14.290.83xyesRev $0.8B, growth 23% (input: historical growth; tapered), Terminal P/S: 1.3x / 1.6x / 1.9x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth$24.520.48xyesMargin ramp: -8% → 12% over 7yr, rev growth 23% (input: historical growth; tapered)
Earnings Power ValueEarnings$4.222.81xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.09B × (1−38%) / WACC 7.1% → EPV (no growth)
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative$6.301.88xyesEBITDA $0.12B × sector EV/EBITDA 8.0x
FCF YieldEarnings$5.942.00xyesFCF $86.7M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$4.962.39xyesSBC-adj FCF $0.08B (FCF $0.09B − SBC $0.01B) capitalized at Kₑ
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset$0.6617.99xyesBV $5.15 × (ROIC 0.9% / WACC 7.1%)
P/Sales SectorRelative$10.991.08xyesRevenue $0.82B × sector P/S 1.5x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$230.2m
Net debt / NOPAT (after-tax)4.77x
Net debt / operating income (pre-tax)2.94x
Interest coverage2.5x
Share count CAGR (buyback)-5.3%
Burning cashno

Bullet Takeaways

Ecovyst is in a strong upcycle: first-quarter 2026 adjusted EBITDA surged 87% to $39.8 million, revenue jumped about 50% to $215 million and beat by 13%, virgin sulfuric acid volumes rose more than 30% with the Waggaman assets, and management raised 2026 guidance to sales of $890 million to $970 million and EBITDA of $180 million to $195 million.

The valuation models disagree sharply: growth and margin-ramp frames mark from $19 to $63, but the conservative book-value and earnings-power frames land between about $4 and $5 (the price is $12.81), reflecting a sub-10% operating margin and a return on invested capital under 1%.

The price embeds roughly 15.7% annual operating growth for five years (about 17x company-wide operating income), within the recent upcycle pace but cyclically dependent; net debt near 3x operating income, interest coverage of about 2.7x, and a consolidating refinery customer base are the structural risks if the cycle turns.

Bull Case

Specialty chemicals are hard to value because the business looks like a commodity producer on the income statement but often behaves like a service company underneath, and Ecovyst is the case where that distinction matters. Its largest line is sulfuric acid regeneration: refineries send spent acid back, Ecovyst reprocesses it and returns it, and the relationship is sticky because the company sits inside the refinery's operating loop through a strategically located network of facilities serving customers with sulfuric acid products and services (FY2025 10-K, accession 0001708035-26-000053). That recurring, contractual service revenue is more durable than the chemical-sector label suggests, and it is precisely what is driving the current results.

The operating leverage in this model is what the first quarter put on display. Adjusted EBITDA surged 87% to $39.8 million from $21.3 million, revenue jumped about 50% to $215 million and beat expectations by nearly 13%, regeneration-services sales grew double digits on high refinery utilization and favorable alkylate economics, and virgin sulfuric acid volumes rose more than 30% with the contribution of the Waggaman assets. When a business with high fixed costs adds volume, the incremental margin is large, which is why EBITDA grew far faster than revenue. The company responded by raising 2026 guidance to sales of $890 million to $970 million and adjusted EBITDA of $180 million to $195 million, and guided second-quarter EBITDA to $50 million to $55 million.

The capital story compounds the operating one. The inversion reads the price as implying roughly 15.7% annual operating growth for five years, which is within what the business has recently delivered during this upcycle, and only the rate's duration, not its plausibility, is the question. For a name where the growth-DCF and exit-multiple frames mark well above the price (the perpetual-growth DCF near $63, the margin-trajectory model near $33), the upside case is that the regeneration franchise and the sulfuric-acid volume hold long enough to validate the operating leverage already showing up in the numbers.

Bear Case

The models disagree sharply on Ecovyst, and when they do, the conservative ones usually tell the more honest story. The book-value and earnings-power frames mark the stock near the floor: simple excess return at about $5.15 (which is just book value per share, because trailing return on equity is negative), two-stage excess return near $4.63, earnings power value near $3.81, and the ROIC-justified book model near $0.65 on a return on invested capital of less than 1%. Against a $12.81 (June 27, 2026) quote, those frames say the business as currently capitalized earns too little on its assets to justify the price. The optimistic models that reach far above the price all lean on extrapolating the current upcycle growth forward, which is exactly the assumption a cyclical chemical company should be most skeptical of.

The earnings quality question is real. The current operating margin is only about 9.9%, and the strength in the latest quarter rests on conditions that are explicitly cyclical: high refinery utilization, favorable alkylate economics, and lower customer downtime than the prior year. Those are good conditions, not permanent ones. When refinery utilization softens or alkylate spreads compress, the regeneration volume and pricing that drove the 87% EBITDA jump can reverse, and a business with a sub-10% operating margin has little room to absorb that.

The balance sheet and customer base add structural fragility. Net debt sits near $230 million against trailing operating income of about $78 million, a net-debt-to-operating-income ratio near 3x with interest coverage of only about 2.7x, which is manageable in an upcycle but tight in a downturn. The customer concentration is a genuine exposure: the 10-K notes that refineries, a sizable subset of the customer base, have undergone significant consolidation with more possible, and that customers may experience financial difficulties including bankruptcies and restructurings (FY2025 10-K, accession 0001708035-26-000053). Fewer, larger refining customers means more pricing power on their side and more revenue at risk if one is lost. The bear case is not that the quarter was bad; it is that the price extrapolates a peak the conservative models refuse to underwrite.

Valuation

Ecovyst is a study in model disagreement, and that disagreement is the valuation. The growth and margin-ramp frames mark far above the price: the perpetual-growth DCF near $63 (on roughly 25% growth carried forward), the margin-trajectory model near $33, the exit-multiple DCF near $23, and the discounted-future-market-cap model near $19. The relative and book-value frames cluster much lower: the sector price-to-sales read near $11, but the asset-based excess-return and earnings-power models land between about $3.81 and $5.15, and the ROIC-justified book model near $0.65. The price is justified by the relative-multiple and growth families; the asset and earnings-power families say expensive.

The split exists because the optimistic models extrapolate the current upcycle while the conservative ones value the business on its normalized, sub-10% margin and its near-zero return on invested capital. For a cyclical specialty chemical name, the conservative frames deserve real weight: a business that earns less than 1% on its full invested base is not creating value at the margin, however strong a given quarter looks.

Inverting the price gives the cleanest single read. At $12.81 the market pays about 17x company-wide operating income, which implies roughly 15.7% annual operating growth for five years at a 9.9% cost of capital. That near-term pace is within what the company has recently delivered during the upcycle, and only about 49% of comparable fast-growers sustained it over a five-year horizon. The honest read: at $12.81 the stock prices in a continuation of the upcycle, and the wide model spread is the market's way of saying the durability of that upcycle is the whole debate.

Catalysts

The most recent print was the first-quarter 2026 report, and it was a clear beat that lifted guidance. Adjusted EBITDA rose 87% to $39.8 million from $21.3 million, revenue grew about 50% to $215 million and surpassed expectations by nearly 13%. Regeneration-services sales grew double digits on high refinery utilization, favorable alkylate economics, and lower customer downtime, while virgin sulfuric acid volumes rose more than 30%, helped by the Waggaman assets.

Management revised 2026 guidance higher: sales of $890 million to $970 million and adjusted EBITDA of $180 million to $195 million, both raised at the low end, with second-quarter adjusted EBITDA guided to $50 million to $55 million on continued regeneration strength and sulfuric acid volume tied to mining demand and the Waggaman contribution. The raised outlook and the strong sequential EBITDA cadence are the near-term catalysts.

The forward thesis tracks the refining and chemical cycle. The supportive drivers are sustained high refinery utilization, favorable alkylate economics, and the ramp of the Waggaman virgin sulfuric acid assets into mining demand. The risks are the cyclicality of all three: refinery utilization and alkylate spreads can soften, and the customer base is concentrated and consolidating, which the company flags as a risk. Watch the quarterly EBITDA cadence against the guided ramp, the durability of regeneration pricing, and virgin sulfuric acid volumes, since those are what separate a real structural step-up from a peak-cycle quarter.

Sources: Ecovyst Q1 2026 results and revised outlook (investor.ecovyst.com, stocktitan.net); Ecovyst Q1 2026 slides (Investing.com); Ecovyst Q1 2026 earnings transcript (AOL, Yahoo Finance).

Peer Cohorts (Per Segment, With Filing Citations)

Ecoservices (consolidated) (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive ECVT report on boothcheck